NCT06011733View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions
Chronic Plaque PsoriasisModerate to Severe Chronic Plaque Psoriasis
Interventions
OTHER

Placebo

Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.

DRUG

Bimekizumab

Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.

Trial Locations (18)

Unknown

Ps0041 20023, Beijing

Ps0041 20247, Beijing

Ps0041 20306, Beijing

Ps0041 20117, Guangzhou

Ps0041 20311, Guangzhou

Ps0041 20313, Guangzhou

Ps0041 20022, Hangzhou

Ps0041 20193, Hangzhou

Ps0041 20296, Hangzhou

Ps0041 20312, Jinan

Ps0041 20318, Jinan

Ps0041 20310, Ningbo

Ps0041 20308, Shanghai

Ps0041 20184, Shenzhen

Ps0041 20136, Tianjin

Ps0041 20120, Wuhan

Ps0041 20314, Wuxi

Ps0041 20309, Xi'an

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT06011733 - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter